eligibility_summary
Eligible: EBV+ metastatic/recurrent NPC, ECOG 0–2, life expectancy >12 wks, creatinine <2.5 mg/dL, AST/ALT <3×ULN, no leukapheresis contraindication, women use contraception to 30 days post infusion, consent. Exclude: symptomatic brain mets, uncontrolled cancers/disease, active HBV/HCV or HIV, major cardiac/cerebrovascular disease, untreated HTN, uncontrolled psych illness, long-term post-transplant immunosuppression (except inhaled steroids), pregnant/nursing or plans ≤2 mo, noncompliance, investigator decision.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
manual_review_required
ai_summary
Intervention: EBV-specific TCR-T cells with a cytokine auto-secreting element (autologous, gene‑engineered adoptive cell therapy). Mechanism: patient T cells are transduced with an EBV-epitope–specific TCR, upon recognizing EBV peptides presented by HLA on nasopharyngeal carcinoma cells, they activate and kill tumor cells. The built‑in cytokine secretion amplifies antitumor immunity by stimulating adaptive T cells and innate NK cells, helping overcome the immunosuppressive tumor microenvironment. Targets: EBV+ tumor cells, antigen presentation/TCR signaling, cytokine signaling.